

Disclosures

ASRS adheres to the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The individuals below have responded that they have no relevant financial relationships with ineligible entities:

Peer Reviewer: **Kevin Blinder, MD**

Planning Committee Members/Speakers:

Ali, Ferhina, MD, MPH, Planner

Witkin, Andre, MD, Planner

Leder, Henry, MD, Planner

Vora, Robin, MD, Planner

The individuals below have disclosed the following financial relationships with ineligible entities:

Planning Committee Members/Speakers/Name of Ineligible Company/Nature of Relationship

Arevalo, J. Fernando, MD, PhD, FACS, FASRS, Speaker

Abbvie, Consultant; Genentech, Consultant; Springer SBM LLC, Royalties or Patent Beneficiary relationship; Topcon Medical Systems Inc, Grant support, ELSEVIER, Royalties or Patent Beneficiary relationship; THEA Laboratories, Consultant; DORC Consultant; Alimera Sciences, Inc, Consultant; EyePoint Pharmaceuticals Consultant

Baumal, Caroline, MD, FASRS, Speaker

Genentech, Consultant; Alcon, Consultant, Zeiss, Speaker Bureau; Novartis, Consultant; Apellis, Speaker Bureau; Regeneron, Speaker Bureau; Ora, Consultant

Kaiser, Peter, MD FASRS, Moderator

Ray Therapeutics, Consultant; Nanoscope Therapeutics, Consultant; Regnex Bio, Consultant; B+L, Consultant; Allergan, Consultant; Allegro, Consultant; Ocular Therapeutic, Consultant; Revopsis, Consultant, Affamed, Consultant; Regeneron, Consultant; Novartis, Consultant; Stealth Biotherapeutics, Consultant; Bayer, Consultant

Schneider, Eric, MD, Speaker

Carl Zeiss Meditec, Consultant, Principal Investigator; Notal Vision, Consultant, Principal Investigator; Oxurion, Principal Investigator; AffaMed Therapeutics, Principal Investigator; OcuTerra Therapeutics, Principal Investigator; Regeneron, Principal Investigator

Vajzovic, Lejla, MD, FASRS, Speaker

AGTC, Principal Investigator

Planning Committee Members/Speakers/Name of Ineligible Company/Nature of Relationship

Kaiser, Peter, MD FASRS, Moderator, Planner

Ray Therapeutics, Consultant; Nanoscope Therapeutics, Consultant; Regnex Bio, Consultant; B+L, Consultant; Allergan, Consultant; Allegro, Consultant; Ocular Therapeutic, Consultant; Revopsis, Consultant, Affamed, Consultant; Regeneron, Consultant; Novartis, Consultant; Stealth Biotherapeutics, Consultant; Bayer, Consultant

Arevalo, J. Fernando, MD, PhD, FACS, FASRS, Planner

Abbvie, Consultant; Genentech, Consultant; Springer SBM LLC, Royalties or Patent Beneficiary relationship; Topcon Medical Systems Inc, Grant support, ELSEVIER, Royalties or Patent Beneficiary relationship; THEA Laboratories, Consultant; DORC Consultant; Alimera Sciences, Inc, Consultant; EyePoint Pharmaceuticals Consultant

Goldberg, Roger, MD, MBA, Planner

Novartis, Advisory Board; Topcon Medical Systems Inc, Advisory Board; Optos PLC, Advisory Board; Roche Pharma, Consultant; B+L, Consultant; Bayer, Advisory Board; Alcon, Consultant; J&J, Consultant; Apellis, Consultant; Allergan, Advisory Board

Baumal, Caroline, MD, FASRS, Planner

Genentech, Consultant; Alcon, Consultant, Zeiss, Speaker Bureau; Novartis, Consultant; Apellis, Speaker Bureau; Regeneron, Speaker Bureau; Ora, Consultant

Choudhry, Netan, MD, FRCS(C) FASRS, Planner

Novartis, Advisory Board, Topcon Medical Systems Inc, Advisory Board, Optos PLC, Advisory Board, Roche Pharma, Consultant, B+L, Consultant, Bayer, Advisory Board, Alcon, Consultant, J&J, Consultant, Apellis, Consultant Allergan Advisory Board

Jain, Nieraj, MD, Planner

Verana Health, Consultant

Kaiser, Peter, MD FASRS, Planner

Ray Therapeutics, Consultant; Nanoscope Therapeutics, Consultant; Regnex Bio, Consultant; B+L, Consultant; Allergan, Consultant; Allegro, Consultant; Ocular Therapeutic, Consultant; Revopsis, Consultant, Affamed, Consultant; Regeneron, Consultant; Novartis, Consultant; Stealth Biotherapeutics, Consultant; Bayer, Consultant

Schneider, Eric, MD, Planner

Carl Zeiss Meditec, Consultant, Principal Investigator; Notal Vision, Consultant, Principal Investigator; Oxurion, Principal Investigator; AffaMed Therapeutics, Principal Investigator; OcuTerra Therapeutics, Principal Investigator; Regeneron, Principal Investigator

Vajzovic, Lejla, MD, FASRS, Planner

AGTC, Principal Investigator

Yoshihiro Yonekawa, MD, FASRS, Planner

Alcon, Consultant; Bausch Health, Consultant; Regeneron, Consultant; Pykus, Consultant; Tarsus, Consultant; Versant Health, Advisory Board